Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    The ReSScue trial. Aiming to Reduce disease-related gastro-intestinal symptoms in patients with Systemic Sclerosis by repeat intestinal infusions of Anaerobic Cultivated Human Intestinal Microbiome (ACHIM); a Phase II, randomized, double-blinded placebo-controlled 12 week followed by a 8 week open-label extension period

    Summary
    EudraCT number
    2019-004400-35
    Trial protocol
    NO  
    Global end of trial date
    27 Jun 2022

    Results information
    Results version number
    v1(current)
    This version publication date
    10 Apr 2025
    First version publication date
    10 Apr 2025
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    2016/1529
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    -
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Oslo University Hospital
    Sponsor organisation address
    Sognsvannveien 20, Oslo, Norway,
    Public contact
    Department of Rheumatology, Oslo University Hospital, resscue@ous-hf.no
    Scientific contact
    Department of Rheumatology, Oslo University Hospital, resscue@ous-hf.no
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    02 Nov 2022
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    27 Jun 2022
    Global end of trial reached?
    Yes
    Global end of trial date
    27 Jun 2022
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    The primary and secondary endpoints of the ReSScue trial will be estimated at week 12, which represents the end of study period 1, while safety and tolerability will be assessed throughout the 26 week study period. In addition, a number of explorative clinical endpoints will be assessed at weeks 12 and 26. The study is designed with repeat scheduled samplings of biological materials, allowing for explorative endpoints on biomarkers during study periods 1 and 2, and later development of research studies at molecular level (see Section 8). • Estimate efficacy of ACHIM compared to placebo on lower GIT symptoms
    Protection of trial subjects
    Strict exclusion-criteria prior to study entry, close monitoring before-during-and after all interventions and during the whole study. Blood-samples and other vital measures were monitored closely. Data monitoring committee has reviewed recruitment, data quality (protocol deviations) and monitored evidence for treatment harm (AEs, SAEs, SUSARs, deaths) twice during the trial.
    Background therapy
    No modifications were implemented to the background-therapies. Specific medications were established as exclusion criteria, as delineated in the study protocol.
    Evidence for comparator
    -
    Actual start date of recruitment
    26 May 2020
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Norway: 67
    Worldwide total number of subjects
    67
    EEA total number of subjects
    67
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    44
    From 65 to 84 years
    23
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    The recruitment period started in September 2020 and the last patient entered the study in February 2022.

    Pre-assignment
    Screening details
    Participants found to be eligible for the ReSScue study at the first screening visit will be instructed to fill out the UCLA-GIT score form and a fecal incontinence assessment form at home once every week, for a minimum period of four weeks before they can come to the baseline visit.

    Period 1
    Period 1 title
    Inclusion period (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Subject, Investigator, Monitor, Data analyst, Carer, Assessor
    Blinding implementation details
    Randomised, Placebo-controlled, double blind.

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Placebo
    Arm description
    Intervention with Undiluted culture medium with no bacteria.
    Arm type
    Placebo

    Investigational medicinal product name
    ACHIM
    Investigational medicinal product code
    Other name
    Anaerobically cultivated human intestinal microbiota
    Pharmaceutical forms
    Gastroenteral solution
    Routes of administration
    Solution for infusion
    Dosage and administration details
    30 ml (109 bacteria /ml culture solution) given as infusion by endoscopy

    Investigational medicinal product name
    Undiluted culture medium with no bacteria
    Investigational medicinal product code
    Other name
    Placebo
    Pharmaceutical forms
    Gastroenteral solution
    Routes of administration
    Gastroenteral use
    Dosage and administration details
    Duodenal infusions of 30 ml undiluted culture medium with no bacteria.

    Arm title
    ACHIM
    Arm description
    Intervention with undiluted anaerobic bacteria culture
    Arm type
    Experimental

    Investigational medicinal product name
    ACHIM
    Investigational medicinal product code
    Other name
    Anaerobically cultivated human intestinal microbiota
    Pharmaceutical forms
    Gastroenteral solution
    Routes of administration
    Solution for infusion
    Dosage and administration details
    30 ml (109 bacteria /ml culture solution) given as infusion by endoscopy

    Number of subjects in period 1
    Placebo ACHIM
    Started
    34
    33
    Completed
    34
    31
    Not completed
    0
    2
         Adverse event, non-fatal
    -
    2

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Placebo
    Reporting group description
    Intervention with Undiluted culture medium with no bacteria.

    Reporting group title
    ACHIM
    Reporting group description
    Intervention with undiluted anaerobic bacteria culture

    Reporting group values
    Placebo ACHIM Total
    Number of subjects
    34 33 67
    Age categorical
    ACHIM -group
    Units: Subjects
        In utero
    0 0 0
        Preterm newborn infants (gestational age < 37 wks)
    0 0 0
        Newborns (0-27 days)
    0 0 0
        Infants and toddlers (28 days-23 months)
    0 0 0
        Children (2-11 years)
    0 0 0
        Adolescents (12-17 years)
    0 0 0
        Adults (18-64 years)
    22 25 47
        From 65-84 years
    12 8 20
        85 years and over
    0 0 0
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    60.1 ( 11.7 ) 57.9 ( 11.5 ) -
    Gender categorical
    Gender description
    Units: Subjects
        Female
    29 33 62
        Male
    5 0 5
    Severity of Baseline symptoms
    Severity of Baseline symptoms measured at Baseline-visit
    Units: Subjects
        Moderate
    7 6 13
        Severe
    27 27 54
    Subject analysis sets

    Subject analysis set title
    Per protocol analysis of ACHIM/placebo from week 0 to week 12.
    Subject analysis set type
    Per protocol
    Subject analysis set description
    Change from baseline to week 12 in UCLA GIT score item diarrhea or bloating, depending which was the worst symptom at the baseline evaluated separately for each patient 12 weeks

    Subject analysis sets values
    Per protocol analysis of ACHIM/placebo from week 0 to week 12.
    Number of subjects
    63
    Age categorical
    ACHIM -group
    Units: Subjects
        In utero
    0
        Preterm newborn infants (gestational age < 37 wks)
    0
        Newborns (0-27 days)
    0
        Infants and toddlers (28 days-23 months)
    0
        Children (2-11 years)
    0
        Adolescents (12-17 years)
    0
        Adults (18-64 years)
    47
        From 65-84 years
    20
        85 years and over
    0
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    58.91 ( 11.59 )
    Gender categorical
    Gender description
    Units: Subjects
        Female
    62
        Male
    5
    Severity of Baseline symptoms
    Severity of Baseline symptoms measured at Baseline-visit
    Units: Subjects
        Moderate
    13
        Severe
    54

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Placebo
    Reporting group description
    Intervention with Undiluted culture medium with no bacteria.

    Reporting group title
    ACHIM
    Reporting group description
    Intervention with undiluted anaerobic bacteria culture

    Subject analysis set title
    Per protocol analysis of ACHIM/placebo from week 0 to week 12.
    Subject analysis set type
    Per protocol
    Subject analysis set description
    Change from baseline to week 12 in UCLA GIT score item diarrhea or bloating, depending which was the worst symptom at the baseline evaluated separately for each patient 12 weeks

    Primary: Primary endpoint

    Close Top of page
    End point title
    Primary endpoint
    End point description
    The model has fixed effects for stratification factor worst symptom, time, treatment and an interaction term between time and treatment. Time is a categorical variable, with levels corresponding to different weeks. Model is adjusted for the baseline worst symptom GIT score. Random intercepts are included. The primary estimate is the treatment effect at change between baseline and 12 weeks and is presented with two-sided 95% confidence intervals.
    End point type
    Primary
    End point timeframe
    The change between baseline and week 12 in the worst symptom GIT score after 12 weeks is analysed here using a linear mixed model, including the worst symptom GIT score value at baseline, 2, 4, 6, and 12 weeks as longitudinal outcome.
    End point values
    Placebo ACHIM Per protocol analysis of ACHIM/placebo from week 0 to week 12.
    Number of subjects analysed
    33
    30
    63
    Units: UCLA GIT score
    33
    30
    63
    Statistical analysis title
    Primary endpoint
    Statistical analysis description
    The change between baseline and week 12 in the worst symptom GIT score after 12 weeks is analysed here using a linear mixed model, including the worst symptom GIT score value at baseline, 2, 4, 6, and 12 weeks as longitudinal outcome. The model has fixed effects for stratification factor worst symptom, time, treatment and an interaction term between time and treatment. Time is a categorical variable, with levels corresponding to different weeks.
    Comparison groups
    ACHIM v Placebo
    Number of subjects included in analysis
    63
    Analysis specification
    Pre-specified
    Analysis type
    superiority [1]
    P-value
    = 0.25 [2]
    Method
    Mixed models analysis
    Parameter type
    AME
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.12
         upper limit
    0.47
    Variability estimate
    Standard deviation
    Notes
    [1] - Continuous primary endpoint “worst symptom derived from UCLA GIT score items diarrhea and bloating” is assessed four times during the screening period and five times during the study Part A1 (at weeks 0, 2, 4, 6, and 12), and will be analyzed using a linear mixed model accounting for the correlations between repeated measurements within each participants by random intercept and slope.
    [2] - Estimates will be presented with two-sided 95% confidence intervals, and p-values smaller than 0.05 will be considered significant. The primary estimate will be the treatment effect (average marginal effect) at 12 weeks.

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    All AE will be collected from the start of intervention until the follow-up visit at the time points specified in the SoA.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    22.0
    Reporting groups
    Reporting group title
    ACHIM
    Reporting group description
    -

    Reporting group title
    Placebo
    Reporting group description
    -

    Serious adverse events
    ACHIM Placebo
    Total subjects affected by serious adverse events
         subjects affected / exposed
    3 / 16 (18.75%)
    1 / 19 (5.26%)
         number of deaths (all causes)
    0
    0
         number of deaths resulting from adverse events
    0
    0
    Cardiac disorders
    Myocardial infarction
    Additional description: Myocardial infarction
         subjects affected / exposed
    2 / 16 (12.50%)
    1 / 19 (5.26%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Nervous system disorders
    Myelitis transverse
    Additional description: Myelitis transverse
         subjects affected / exposed
    2 / 16 (12.50%)
    1 / 19 (5.26%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Acute abdomen
    Additional description: Acute abdomen
         subjects affected / exposed
    2 / 16 (12.50%)
    1 / 19 (5.26%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    ACHIM Placebo
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    16 / 16 (100.00%)
    19 / 19 (100.00%)
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Neoplasm skin
         subjects affected / exposed
    2 / 16 (12.50%)
    0 / 19 (0.00%)
         occurrences all number
    2
    0
    Vascular disorders
    Hypotension
         subjects affected / exposed
    1 / 16 (6.25%)
    1 / 19 (5.26%)
         occurrences all number
    1
    1
    Raynaud's phenomenon
         subjects affected / exposed
    0 / 16 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    1
    Surgical and medical procedures
    Knee operation
         subjects affected / exposed
    0 / 16 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    1
    General disorders and administration site conditions
    Calcinosis
    Additional description: Calcinosis
         subjects affected / exposed
    1 / 16 (6.25%)
    0 / 19 (0.00%)
         occurrences all number
    1
    0
    Chest discomfort
    Additional description: Chest discomfort
         subjects affected / exposed
    0 / 16 (0.00%)
    11 / 19 (57.89%)
         occurrences all number
    0
    1
    Fatigue
    Additional description: Fatigue
         subjects affected / exposed
    5 / 16 (31.25%)
    5 / 19 (26.32%)
         occurrences all number
    5
    5
    Reproductive system and breast disorders
    Menopausal symptoms
         subjects affected / exposed
    0 / 16 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    1
    Respiratory, thoracic and mediastinal disorders
    Dyspnoea
         subjects affected / exposed
    0 / 16 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    1
    Pneumonia aspiration
         subjects affected / exposed
    0 / 16 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    1
    Psychiatric disorders
    Emotional disorder
         subjects affected / exposed
    0 / 16 (0.00%)
    2 / 19 (10.53%)
         occurrences all number
    0
    2
    Sleep disorder
         subjects affected / exposed
    0 / 16 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    1
    Nervous system disorders
    Dizziness
         subjects affected / exposed
    0 / 16 (0.00%)
    2 / 19 (10.53%)
         occurrences all number
    0
    2
    Fine motor skill dysfunction
         subjects affected / exposed
    1 / 16 (6.25%)
    0 / 19 (0.00%)
         occurrences all number
    1
    0
    Headache
         subjects affected / exposed
    1 / 16 (6.25%)
    2 / 19 (10.53%)
         occurrences all number
    1
    2
    Blood and lymphatic system disorders
    Anemia
    Additional description: Anemia
         subjects affected / exposed
    1 / 16 (6.25%)
    1 / 19 (5.26%)
         occurrences all number
    1
    1
    Iron deficiency anemia
    Additional description: Iron deficiency anemia
         subjects affected / exposed
    0 / 16 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    1
    Leukopenia
    Additional description: Leukopenia
         subjects affected / exposed
    0 / 16 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    1
    Neutropenia
    Additional description: Neutropenia
         subjects affected / exposed
    0 / 16 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    1
    Eye disorders
    Dry eye
    Additional description: Dry eye
         subjects affected / exposed
    0 / 16 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    1
    Gastrointestinal disorders
    Abdominal discomfort
    Additional description: Abdominal discomfort
         subjects affected / exposed
    1 / 16 (6.25%)
    2 / 19 (10.53%)
         occurrences all number
    1
    2
    Abdominal distension
    Additional description: Abdominal distension
         subjects affected / exposed
    1 / 16 (6.25%)
    1 / 19 (5.26%)
         occurrences all number
    1
    1
    Abdominal pain
    Additional description: Abdominal pain
         subjects affected / exposed
    5 / 16 (31.25%)
    2 / 19 (10.53%)
         occurrences all number
    5
    2
    Abdominal pain upper
    Additional description: Abdominal pain upper
         subjects affected / exposed
    2 / 16 (12.50%)
    1 / 19 (5.26%)
         occurrences all number
    2
    1
    Anal Incontinence
    Additional description: Anal Incontinence
         subjects affected / exposed
    1 / 16 (6.25%)
    0 / 19 (0.00%)
         occurrences all number
    1
    0
    anal prolaps
    Additional description: anal prolaps
         subjects affected / exposed
    1 / 16 (6.25%)
    0 / 19 (0.00%)
         occurrences all number
    1
    0
    Diarrhoea
    Additional description: Diarrhoea
         subjects affected / exposed
    2 / 16 (12.50%)
    2 / 19 (10.53%)
         occurrences all number
    2
    2
    Dry mouth
    Additional description: Dry mouth
         subjects affected / exposed
    0 / 16 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    1
    Eructation
    Additional description: Eructation
         subjects affected / exposed
    1 / 16 (6.25%)
    0 / 19 (0.00%)
         occurrences all number
    1
    0
    Flatulence
    Additional description: Flatulence
         subjects affected / exposed
    1 / 16 (6.25%)
    0 / 19 (0.00%)
         occurrences all number
    1
    0
    Nausea
    Additional description: Nausea
         subjects affected / exposed
    3 / 16 (18.75%)
    4 / 19 (21.05%)
         occurrences all number
    3
    4
    Oesophagitis
    Additional description: Oesophagitis
         subjects affected / exposed
    1 / 16 (6.25%)
    0 / 19 (0.00%)
         occurrences all number
    1
    0
    Vomiting
    Additional description: Vomiting
         subjects affected / exposed
    2 / 16 (12.50%)
    1 / 19 (5.26%)
         occurrences all number
    2
    1
    Hepatobiliary disorders
    Hepatitis
    Additional description: Hepatitis
         subjects affected / exposed
    1 / 16 (6.25%)
    0 / 19 (0.00%)
         occurrences all number
    1
    0
    Skin and subcutaneous tissue disorders
    Alopecia
         subjects affected / exposed
    1 / 16 (6.25%)
    2 / 19 (10.53%)
         occurrences all number
    1
    2
    Cutaneous calcification
         subjects affected / exposed
    1 / 16 (6.25%)
    0 / 19 (0.00%)
         occurrences all number
    1
    0
    Dry skin
         subjects affected / exposed
    0 / 16 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    1
    Pruritus
         subjects affected / exposed
    0 / 16 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    1
    skin ulcer
         subjects affected / exposed
    1 / 16 (6.25%)
    0 / 19 (0.00%)
         occurrences all number
    1
    0
    Renal and urinary disorders
    Urge incontinence
         subjects affected / exposed
    1 / 16 (6.25%)
    0 / 19 (0.00%)
         occurrences all number
    1
    0
    Urinary incontinence
         subjects affected / exposed
    1 / 16 (6.25%)
    0 / 19 (0.00%)
         occurrences all number
    1
    0
    Musculoskeletal and connective tissue disorders
    Arthralgia
    Additional description: Arthralgia
         subjects affected / exposed
    5 / 16 (31.25%)
    3 / 19 (15.79%)
         occurrences all number
    5
    3
    Back pain
    Additional description: Back pain
         subjects affected / exposed
    0 / 16 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    1
    Joint stiffness
    Additional description: Joint stiffness
         subjects affected / exposed
    1 / 16 (6.25%)
    0 / 19 (0.00%)
         occurrences all number
    1
    0
    Joint swelling
    Additional description: Joint swelling
         subjects affected / exposed
    1 / 16 (6.25%)
    0 / 19 (0.00%)
         occurrences all number
    1
    0
    Limb discomfort
    Additional description: Limb discomfort
         subjects affected / exposed
    0 / 16 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    1
    Muscle spasms
    Additional description: Muscle spasms
         subjects affected / exposed
    1 / 16 (6.25%)
    1 / 19 (5.26%)
         occurrences all number
    1
    1
    Musculoskeletal stiffness
    Additional description: Musculoskeletal stiffness
         subjects affected / exposed
    1 / 16 (6.25%)
    0 / 19 (0.00%)
         occurrences all number
    1
    0
    Myalgia
    Additional description: Myalgia
         subjects affected / exposed
    1 / 16 (6.25%)
    0 / 19 (0.00%)
         occurrences all number
    1
    0
    Pain in extremity
         subjects affected / exposed
    1 / 16 (6.25%)
    0 / 19 (0.00%)
         occurrences all number
    1
    0
    Tendonitis
         subjects affected / exposed
    0 / 16 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    1
    Infections and infestations
    Candida infection
    Additional description: Candida infection
         subjects affected / exposed
    0 / 16 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    1
    Erythema migrans
    Additional description: Erythema migrans
         subjects affected / exposed
    0 / 16 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    1
    Staphylococcal infection
    Additional description: Staphylococcal infection
         subjects affected / exposed
    1 / 16 (6.25%)
    0 / 19 (0.00%)
         occurrences all number
    1
    0
    Tooth infection
    Additional description: Tooth infection
         subjects affected / exposed
    0 / 16 (0.00%)
    2 / 19 (10.53%)
         occurrences all number
    0
    2
    Metabolism and nutrition disorders
    Decreased appetite
    Additional description: Decreased appetite
         subjects affected / exposed
    0 / 16 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    1

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? No

    Interruptions (globally)

    Were there any global interruptions to the trial? Yes
    Date
    Interruption
    Restart date
    19 Mar 2021
    Stop in new inclusions due to ongoing Covid-19 pandemic
    10 May 2021

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 06:31:03 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA